Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates;Recomendaciones para la prevención, diagnóstico y tratamiento de osteonecrosis de los maxilares (ONM) en pacientes con cáncer tratados con bisfosfonatos

Medicina Oral, Patologia Oral y Cirugia Bucal

Volumn 12, Issue 4, 2007, Pages 279-283

  Bagán, José V ^a,b,m   Blade, Juan ^c   Cozar, José Manuel ^d   Constela, Manuel ^e   Sanz, Ramón García ^f   Veiga, Francisco Gómez ^g   Lahuerta, Juan José ^h   Lluch, Ana ⁱ   Massuti, Bartomeu ^j   Morote, Juan ^k   San Miguel, Jesús F ^f   Solsona, Eduardo ^l  

^a UNIVERSITY OF VALENCIA   (Spain)

^b Hospital General de Valencia   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^e HOSPITAL MONTECELO   (Spain)

^f HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^g HOSPITAL JUAN CANALEJO   (Spain)

^h HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

ⁱ HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^j HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^k HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^l INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^m HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CHLORHEXIDINE; CLINDAMYCIN; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ARTICLE; BONE NECROSIS; BREAST CANCER; CANCER PATIENT; DIAGNOSTIC PROCEDURE; DRUG MECHANISM; HUMAN; HYPERCALCEMIA; JAW DISEASE; MULTIPLE MYELOMA; ODONTOLOGY; PROSTATE CANCER; CHEMICALLY INDUCED DISORDER; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; NEOPLASM; PRACTICE GUIDELINE;

DIPHOSPHONATES; HUMANS; JAW DISEASES; NEOPLASMS; OSTEONECROSIS; PRACTICE GUIDELINES;

EID: 34547588611     PISSN: 16984447     EISSN: 16986946     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Bagan JV, Jimenez Y, Murillo J, Hernandez S, Poveda R, Sanchis JM, et al. Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases. Oral Oncol 2006;42:327-9.
2. Bagán JV, Murillo J, Jiménez Y, Poveda R, Milián MA, Sanchis JM, et al. Cancer chemotherapy induced avascular jaw osteonecrosis: series of 10 cases. J oral Pathol Med 2005;34:120-3.
3. Heymann D, Ory B, Gouin F, Green JR, Redini F. Bisphosphonates: new therapeutic agents for the treatment of bone tumours. Trends in Molecular Medicine 2004;10:337-43.
4. Hohneker JA. Novartis Oncology. September 2004. http://www.novatis.com
5. Kyle RA, Yee GC, Somerfield MR, Flynn PJ, Halabi S, Jagannath S Orlowski RZ, Roodman DG, Twilde P, Anderson K. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2007 Jun 10;25(17):2464-72. Epub 2007 May 21. PMID: 17515569 [PubMed - in process].
6. Lacy, M.Q.; Dispenzieri, A.; Gertz, M.A.; Greipp, P.R.; Gollbach, K.L.; Hayman, S.R. et all. Mayo Clinic Consensus Statement For The Use Of Bisphosphonates In Multiple Myeloma. Mayo Clin Proc. August 2006;81(8):1047- 1053.
7. Lugassy G, Shaham R, Nemets A, Ben-Dor D, Nahlieli O. severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: a new clinical entity. American J Med 2004;15: 440-1.
8. Marx RE. Pamidronate (Aredia) and Zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115.
9. Ruggiero, S.; Gralow, J.; Marx, R.E.; Hoff, A.O.; Schubert, M.M.; Huryn, J.M. et all. Practical Guidelines for the Prevention, Diagnosis, and Treatment of Osteonecrosis of the Jaw in Patients With Cancer. Journal Of Oncology Practice January 2006, Vol. 2, Issue 1.
10. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of Bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-34.
11. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, et al. Novel antiangiogenic effects of the bisphosphonates compound zoledronic acid. J Pharmacol Exp Ther 2002;302:1055-61.